News stories about CIGNA (NYSE:CI) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CIGNA earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the health services provider an impact score of 45.4495742908514 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
CI has been the topic of several research reports. Credit Suisse Group boosted their price objective on shares of CIGNA from $215.00 to $218.00 and gave the company an “outperform” rating in a research report on Friday, May 4th. Zacks Investment Research raised shares of CIGNA from a “hold” rating to a “buy” rating and set a $197.00 price objective on the stock in a research report on Monday, May 28th. Barclays initiated coverage on shares of CIGNA in a research report on Thursday, March 8th. They issued an “overweight” rating and a $235.00 price objective on the stock. Sanford C. Bernstein initiated coverage on shares of CIGNA in a research report on Tuesday, March 13th. They issued a “market perform” rating and a $194.00 price objective on the stock. Finally, Goldman Sachs Group raised shares of CIGNA from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $193.00 to $212.00 in a research report on Wednesday, June 6th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. CIGNA presently has an average rating of “Buy” and a consensus price target of $217.00.
Shares of NYSE:CI opened at $174.08 on Friday. The company has a current ratio of 0.35, a quick ratio of 0.35 and a debt-to-equity ratio of 0.37. CIGNA has a one year low of $163.02 and a one year high of $227.13. The stock has a market cap of $42.57 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 1.09 and a beta of 0.58.
CIGNA (NYSE:CI) last issued its quarterly earnings results on Thursday, May 3rd. The health services provider reported $4.11 EPS for the quarter, topping the consensus estimate of $3.39 by $0.72. CIGNA had a net margin of 5.99% and a return on equity of 20.90%. The firm had revenue of $11.38 billion for the quarter, compared to analysts’ expectations of $10.97 billion. During the same period in the previous year, the firm posted $2.77 EPS. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. equities analysts forecast that CIGNA will post 13.24 EPS for the current fiscal year.
In other news, Director William D. Zollars sold 265 shares of the company’s stock in a transaction dated Thursday, June 14th. The shares were sold at an average price of $176.93, for a total value of $46,886.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Hoeltzel Mary T. Agoglia sold 1,000 shares of the company’s stock in a transaction dated Friday, May 25th. The shares were sold at an average price of $176.19, for a total transaction of $176,190.00. Following the completion of the sale, the vice president now directly owns 4,635 shares in the company, valued at $816,640.65. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.
CIGNA Company Profile
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.
Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.